-
2
-
-
0032748385
-
Antitumor activity of thalidomide in refractory multiple myeloma
-
Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
-
(1999)
N Engl J Med
, vol.341
, pp. 1565-1571
-
-
Singhal, S.1
Mehta, J.2
Desikan, R.3
Ayers, D.4
Roberson, P.5
Eddlemon, P.6
-
3
-
-
0035883101
-
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
-
Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98 (2001) 958-965
-
(2001)
Blood
, vol.98
, pp. 958-965
-
-
Raza, A.1
Meyer, P.2
Dutt, D.3
Zorat, F.4
Lisak, L.5
Nascimben, F.6
-
4
-
-
0035881040
-
Treatment of Waldenstrom's macroglobulinemia with thalidomide
-
Dimopoulos M.A., Zomas A., Viniou N.A., Grigoraki V., Galani E., Matsouka C., et al. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 19 (2001) 3596-3601
-
(2001)
J Clin Oncol
, vol.19
, pp. 3596-3601
-
-
Dimopoulos, M.A.1
Zomas, A.2
Viniou, N.A.3
Grigoraki, V.4
Galani, E.5
Matsouka, C.6
-
5
-
-
0036464605
-
Efficacy and safety of thalidomide in patients with acute myeloid leukemia
-
Steins M.B., Padro T., Bieker R., Ruiz S., Kropff M., Kienast J., et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 99 (2002) 834-839
-
(2002)
Blood
, vol.99
, pp. 834-839
-
-
Steins, M.B.1
Padro, T.2
Bieker, R.3
Ruiz, S.4
Kropff, M.5
Kienast, J.6
-
6
-
-
0034928836
-
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia
-
Barosi G., Grossi A., Comotti B., Musto P., Gamba G., and Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 114 (2001) 78-83
-
(2001)
Br J Haematol
, vol.114
, pp. 78-83
-
-
Barosi, G.1
Grossi, A.2
Comotti, B.3
Musto, P.4
Gamba, G.5
Marchetti, M.6
-
7
-
-
5344258973
-
Adverse effects of thalidomide administration in patients with neoplastic diseases
-
Dimopoulos M.A., and Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117 (2004) 508-515
-
(2004)
Am J Med
, vol.117
, pp. 508-515
-
-
Dimopoulos, M.A.1
Eleutherakis-Papaiakovou, V.2
-
8
-
-
0035469858
-
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
-
Zangari M., Anaissie E., Barlogie B., Badros A., Desikan R., Gopal A.V., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001) 1614-1615
-
(2001)
Blood
, vol.98
, pp. 1614-1615
-
-
Zangari, M.1
Anaissie, E.2
Barlogie, B.3
Badros, A.4
Desikan, R.5
Gopal, A.V.6
-
9
-
-
33745291997
-
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations
-
Hussein M.A. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 95 (2006) 924-930
-
(2006)
Thromb Haemost
, vol.95
, pp. 924-930
-
-
Hussein, M.A.1
-
11
-
-
0036843032
-
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
-
Rajkumar S.V., Hayman S., Gertz M.A., Dispenzieri A., Lacy M.Q., Greipp P.R., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20 (2002) 4319-4323
-
(2002)
J Clin Oncol
, vol.20
, pp. 4319-4323
-
-
Rajkumar, S.V.1
Hayman, S.2
Gertz, M.A.3
Dispenzieri, A.4
Lacy, M.Q.5
Greipp, P.R.6
-
12
-
-
0037103292
-
-
Zangari M., Siegel E., Barlogie B., Anaissie E., Saghafifar F., Fassas A., et al., Morris C., Fink L., Tricot G.A.T.a.o.d.i.m.p.r.t.: i.f.t. Blood 100 (2002) 1168-1171
-
(2002)
Blood
, vol.100
, pp. 1168-1171
-
-
Zangari, M.1
Siegel, E.2
Barlogie, B.3
Anaissie, E.4
Saghafifar, F.5
Fassas, A.6
-
13
-
-
0037370067
-
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer
-
Horne III M.K., Figg W.D., Arlen P., Gulley J., Parker C., Lakhani N., et al. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 23 (2003) 315-318
-
(2003)
Pharmacotherapy
, vol.23
, pp. 315-318
-
-
Horne III, M.K.1
Figg, W.D.2
Arlen, P.3
Gulley, J.4
Parker, C.5
Lakhani, N.6
-
14
-
-
0037393945
-
Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha
-
Steurer M., Sudmeier I., Stauder R., and Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 121 (2003) 101-103
-
(2003)
Br J Haematol
, vol.121
, pp. 101-103
-
-
Steurer, M.1
Sudmeier, I.2
Stauder, R.3
Gastl, G.4
-
15
-
-
0141452131
-
Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin
-
Wun T., Law L., Harvey D., Sieracki B., Scudder S.A., and Ryu J.K. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98 (2003) 1514-1520
-
(2003)
Cancer
, vol.98
, pp. 1514-1520
-
-
Wun, T.1
Law, L.2
Harvey, D.3
Sieracki, B.4
Scudder, S.A.5
Ryu, J.K.6
-
16
-
-
0028025601
-
Erythropoietin increases hemoglobin during radiation therapy for cervical cancer
-
Dusenbery K.E., McGuire W.A., Holt P.J., Carson L.F., Fowler J.M., Twiggs L.B., et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 29 (1994) 1079-1084
-
(1994)
Int J Radiat Oncol Biol Phys
, vol.29
, pp. 1079-1084
-
-
Dusenbery, K.E.1
McGuire, W.A.2
Holt, P.J.3
Carson, L.F.4
Fowler, J.M.5
Twiggs, L.B.6
-
17
-
-
4644220200
-
Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study
-
Lavey R.S., Liu P.Y., Greer B.E., Robinson III W.R., Chang P.C., Wynn R.B., et al. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol 95 (2004) 145-151
-
(2004)
Gynecol Oncol
, vol.95
, pp. 145-151
-
-
Lavey, R.S.1
Liu, P.Y.2
Greer, B.E.3
Robinson III, W.R.4
Chang, P.C.5
Wynn, R.B.6
-
18
-
-
0033168605
-
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
-
Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163 (1999) 380-386
-
(1999)
J Immunol
, vol.163
, pp. 380-386
-
-
Corral, L.G.1
Haslett, P.A.2
Muller, G.W.3
Chen, R.4
Wong, L.M.5
Ocampo, C.J.6
-
19
-
-
0033532557
-
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production
-
Muller G.W., Chen R., Huang S.Y., Corral L.G., Wong L.M., Patterson R.T., et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9 (1999) 1625-1630
-
(1999)
Bioorg Med Chem Lett
, vol.9
, pp. 1625-1630
-
-
Muller, G.W.1
Chen, R.2
Huang, S.Y.3
Corral, L.G.4
Wong, L.M.5
Patterson, R.T.6
-
20
-
-
0035195019
-
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
-
Gupta D., Treon S.P., Shima Y., Hideshima T., Podar K., Tai Y.T., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15 (2001) 1950-1961
-
(2001)
Leukemia
, vol.15
, pp. 1950-1961
-
-
Gupta, D.1
Treon, S.P.2
Shima, Y.3
Hideshima, T.4
Podar, K.5
Tai, Y.T.6
-
21
-
-
27744492561
-
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
-
Rajkumar S.V., Hayman S.R., Lacy M.Q., Dispenzieri A., Geyer S.M., Kabat B., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
-
(2005)
Blood
, vol.106
, pp. 4050-4053
-
-
Rajkumar, S.V.1
Hayman, S.R.2
Lacy, M.Q.3
Dispenzieri, A.4
Geyer, S.M.5
Kabat, B.6
-
22
-
-
33646494190
-
Lenalidomide and venous thrombosis in multiple myeloma
-
Knight R., DeLap R.J., and Zeldis J.B. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354 (2006) 2079-2080
-
(2006)
N Engl J Med
, vol.354
, pp. 2079-2080
-
-
Knight, R.1
DeLap, R.J.2
Zeldis, J.B.3
-
23
-
-
3242787246
-
Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor
-
Tobu M., Iqbal O., Fareed D., Chatha M., Hoppensteadt D., Bansal V., et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 10 (2004) 225-232
-
(2004)
Clin Appl Thromb Hemost
, vol.10
, pp. 225-232
-
-
Tobu, M.1
Iqbal, O.2
Fareed, D.3
Chatha, M.4
Hoppensteadt, D.5
Bansal, V.6
-
24
-
-
4344693453
-
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
-
Schey S.A., Fields P., Bartlett J.B., Clarke I.A., Ashan G., Knight R.D., et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22 (2004) 3269-3276
-
(2004)
J Clin Oncol
, vol.22
, pp. 3269-3276
-
-
Schey, S.A.1
Fields, P.2
Bartlett, J.B.3
Clarke, I.A.4
Ashan, G.5
Knight, R.D.6
-
25
-
-
16244363678
-
Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis
-
Streetly M., Hunt B.J., Parmar K., Jones R., Zeldis J., and Schey S. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol 74 (2005) 293-296
-
(2005)
Eur J Haematol
, vol.74
, pp. 293-296
-
-
Streetly, M.1
Hunt, B.J.2
Parmar, K.3
Jones, R.4
Zeldis, J.5
Schey, S.6
-
26
-
-
33751074915
-
Myeloma, thalidomide and thrombosis
-
Honemann D., and Prince H.M. Myeloma, thalidomide and thrombosis. Leuk Lymphoma 47 (2006) 2273-2275
-
(2006)
Leuk Lymphoma
, vol.47
, pp. 2273-2275
-
-
Honemann, D.1
Prince, H.M.2
-
27
-
-
33750067977
-
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102)
-
Krown S.E., Niedzwiecki D., Hwu W.J., Hodgson L., Houghton A.N., and Haluska F.G. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 107 (2006) 1883-1890
-
(2006)
Cancer
, vol.107
, pp. 1883-1890
-
-
Krown, S.E.1
Niedzwiecki, D.2
Hwu, W.J.3
Hodgson, L.4
Houghton, A.N.5
Haluska, F.G.6
-
28
-
-
13244256953
-
Arterial thrombosis in four patients treated with thalidomide
-
Scarpace S.L., Hahn T., Roy H., Brown K., Paplham P., Chanan-Khan A., et al. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma 46 (2005) 239-242
-
(2005)
Leuk Lymphoma
, vol.46
, pp. 239-242
-
-
Scarpace, S.L.1
Hahn, T.2
Roy, H.3
Brown, K.4
Paplham, P.5
Chanan-Khan, A.6
-
29
-
-
33748700214
-
Acquired activated protein C resistance and thrombosis in multiple myeloma patients
-
Jimenez-Zepeda V.H., and Dominguez-Martinez V.J. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 4 (2006) 11
-
(2006)
Thromb J
, vol.4
, pp. 11
-
-
Jimenez-Zepeda, V.H.1
Dominguez-Martinez, V.J.2
-
30
-
-
0642341991
-
Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment
-
Minnema M.C., Fijnheer R., De Groot P.G., and Lokhorst H.M. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 1 (2003) 445-449
-
(2003)
J Thromb Haemost
, vol.1
, pp. 445-449
-
-
Minnema, M.C.1
Fijnheer, R.2
De Groot, P.G.3
Lokhorst, H.M.4
-
31
-
-
0036526384
-
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
-
Zangari M., Saghafifar F., Anaissie E., Badros A., Desikan R., Fassas A., et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13 (2002) 187-192
-
(2002)
Blood Coagul Fibrinolysis
, vol.13
, pp. 187-192
-
-
Zangari, M.1
Saghafifar, F.2
Anaissie, E.3
Badros, A.4
Desikan, R.5
Fassas, A.6
-
32
-
-
0036645524
-
Endothelial dysfunction in antiangiogenesis-associated thrombosis
-
Kaushal V., Kohli M., Zangari M., Fink L., and Mehta P. Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol 20 (2002) 3042-3043
-
(2002)
J Clin Oncol
, vol.20
, pp. 3042-3043
-
-
Kaushal, V.1
Kohli, M.2
Zangari, M.3
Fink, L.4
Mehta, P.5
-
33
-
-
0029767998
-
Apoptosis is associated with increased cell surface tissue factor procoagulant activity
-
Greeno E.W., Bach R.R., and Moldow C.F. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 75 (1996) 281-289
-
(1996)
Lab Invest
, vol.75
, pp. 281-289
-
-
Greeno, E.W.1
Bach, R.R.2
Moldow, C.F.3
-
35
-
-
3242760702
-
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma
-
Cavo M., Zamagni E., Tosi P., Cellini C., Cangini D., Tacchetti P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89 (2004) 826-831
-
(2004)
Haematologica
, vol.89
, pp. 826-831
-
-
Cavo, M.1
Zamagni, E.2
Tosi, P.3
Cellini, C.4
Cangini, D.5
Tacchetti, P.6
-
36
-
-
33751103917
-
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism
-
Miller K.C., Padmanabhan S., Dimicelli L., Depaolo D., Landrigan B., Yu J., et al. Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma 47 (2006) 2339-2343
-
(2006)
Leuk Lymphoma
, vol.47
, pp. 2339-2343
-
-
Miller, K.C.1
Padmanabhan, S.2
Dimicelli, L.3
Depaolo, D.4
Landrigan, B.5
Yu, J.6
-
37
-
-
33646883735
-
Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis
-
Ikhlaque N., Seshadri V., Kathula S., and Baumann M.A. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 81 (2006) 420-422
-
(2006)
Am J Hematol
, vol.81
, pp. 420-422
-
-
Ikhlaque, N.1
Seshadri, V.2
Kathula, S.3
Baumann, M.A.4
-
38
-
-
33746593667
-
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide
-
Palumbo A., Rus C., Zeldis J.B., Rodeghiero F., and Boccadoro M. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 4 (2006) 1842-1845
-
(2006)
J Thromb Haemost
, vol.4
, pp. 1842-1845
-
-
Palumbo, A.1
Rus, C.2
Zeldis, J.B.3
Rodeghiero, F.4
Boccadoro, M.5
-
39
-
-
4544332965
-
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
-
Zangari M., Barlogie B., Anaissie E., Saghafifar F., Eddlemon P., Jacobson J., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126 (2004) 715-721
-
(2004)
Br J Haematol
, vol.126
, pp. 715-721
-
-
Zangari, M.1
Barlogie, B.2
Anaissie, E.3
Saghafifar, F.4
Eddlemon, P.5
Jacobson, J.6
-
40
-
-
19944368366
-
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy
-
Minnema M.C., Breitkreutz I., Auwerda J.J., van der H.B., Cremer F.W., van Marion A.M., et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18 (2004) 2044-2046
-
(2004)
Leukemia
, vol.18
, pp. 2044-2046
-
-
Minnema, M.C.1
Breitkreutz, I.2
Auwerda, J.J.3
van der, H.B.4
Cremer, F.W.5
van Marion, A.M.6
-
41
-
-
28544436819
-
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma
-
Baz R., Li L., Kottke-Marchant K., Srkalovic G., McGowan B., Yiannaki E., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80 (2005) 1568-1574
-
(2005)
Mayo Clin Proc
, vol.80
, pp. 1568-1574
-
-
Baz, R.1
Li, L.2
Kottke-Marchant, K.3
Srkalovic, G.4
McGowan, B.5
Yiannaki, E.6
-
42
-
-
33845442041
-
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer
-
Bennett C.L., Angelotta C., Yarnold P.R., Evens A.M., Zonder J.A., Raisch D.W., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296 (2006) 2558-2560
-
(2006)
JAMA
, vol.296
, pp. 2558-2560
-
-
Bennett, C.L.1
Angelotta, C.2
Yarnold, P.R.3
Evens, A.M.4
Zonder, J.A.5
Raisch, D.W.6
-
43
-
-
33846318493
-
Risk of thrombosis with lenalidomide and its prevention with aspirin
-
Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest 131 (2007) 275-277
-
(2007)
Chest
, vol.131
, pp. 275-277
-
-
Hirsh, J.1
-
44
-
-
34249660457
-
Pathogenesis, clinical and laboratory aspects of thrombosis in cancer
-
Franchini M., Montagnana M., Targher G., Manzato F., and Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 24 (2007) 29-38
-
(2007)
J Thromb Thrombolysis
, vol.24
, pp. 29-38
-
-
Franchini, M.1
Montagnana, M.2
Targher, G.3
Manzato, F.4
Lippi, G.5
-
45
-
-
0037775584
-
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
-
Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
-
(2003)
N Engl J Med
, vol.349
, pp. 146-153
-
-
Lee, A.Y.1
Levine, M.N.2
Baker, R.I.3
Bowden, C.4
Kakkar, A.K.5
Prins, M.6
-
46
-
-
0037067889
-
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study
-
Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 (2002) 1729-1735
-
(2002)
Arch Intern Med
, vol.162
, pp. 1729-1735
-
-
Meyer, G.1
Marjanovic, Z.2
Valcke, J.3
Lorcerie, B.4
Gruel, Y.5
Solal-Celigny, P.6
-
47
-
-
0025141337
-
What is the evidence that tumors are angiogenesis dependent?
-
Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
-
(1990)
J Natl Cancer Inst
, vol.82
, pp. 4-6
-
-
Folkman, J.1
-
48
-
-
0030576517
-
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
-
Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
-
(1996)
Cell
, vol.86
, pp. 353-364
-
-
Hanahan, D.1
Folkman, J.2
-
49
-
-
0037208589
-
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
-
Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
-
(2003)
J Clin Oncol
, vol.21
, pp. 60-65
-
-
Kabbinavar, F.1
Hurwitz, H.I.2
Fehrenbacher, L.3
Meropol, N.J.4
Novotny, W.F.5
Lieberman, G.6
-
50
-
-
17844373871
-
Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy
-
Shah M.A., Ilson D., and Kelsen D.P. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23 (2005) 2574-2576
-
(2005)
J Clin Oncol
, vol.23
, pp. 2574-2576
-
-
Shah, M.A.1
Ilson, D.2
Kelsen, D.P.3
-
51
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
-
52
-
-
20544478429
-
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial
-
Kabbinavar F.F., Schulz J., McCleod M., Patel T., Hamm J.T., Hecht J.R., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705
-
(2005)
J Clin Oncol
, vol.23
, pp. 3697-3705
-
-
Kabbinavar, F.F.1
Schulz, J.2
McCleod, M.3
Patel, T.4
Hamm, J.T.5
Hecht, J.R.6
-
53
-
-
2942621888
-
Bevacizumab in the treatment of breast cancer: rationale and current data
-
Rugo H.S. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9 Suppl. 1 (2004) 43-49
-
(2004)
Oncologist
, vol.9
, Issue.SUPPL. 1
, pp. 43-49
-
-
Rugo, H.S.1
-
54
-
-
2942526896
-
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?
-
Herbst R.S., and Sandler A.B. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?. Oncologist 9 Suppl 1 (2004) 19-26
-
(2004)
Oncologist
, vol.9
, Issue.SUPPL. 1
, pp. 19-26
-
-
Herbst, R.S.1
Sandler, A.B.2
-
55
-
-
24344442899
-
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
-
Scappaticci F.A., Fehrenbacher L., Cartwright T., Hainsworth J.D., Heim W., Berlin J., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
-
(2005)
J Surg Oncol
, vol.91
, pp. 173-180
-
-
Scappaticci, F.A.1
Fehrenbacher, L.2
Cartwright, T.3
Hainsworth, J.D.4
Heim, W.5
Berlin, J.6
-
56
-
-
33846484966
-
Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma
-
Frangie C., Lefaucheur C., Medioni J., Jacquot C., Hill G.S., and Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 8 (2007) 177-178
-
(2007)
Lancet Oncol
, vol.8
, pp. 177-178
-
-
Frangie, C.1
Lefaucheur, C.2
Medioni, J.3
Jacquot, C.4
Hill, G.S.5
Nochy, D.6
-
57
-
-
33845353863
-
Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta
-
Yoon S., Schmassmann-Suhijar D., Zuber M., Konietzny P., and Schmassmann A. Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta. Ann Oncol 17 (2006) 1851-1852
-
(2006)
Ann Oncol
, vol.17
, pp. 1851-1852
-
-
Yoon, S.1
Schmassmann-Suhijar, D.2
Zuber, M.3
Konietzny, P.4
Schmassmann, A.5
-
58
-
-
15444378057
-
Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer
-
Neagoe P.E., Lemieux C., and Sirois M.G. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem 280 (2005) 9904-9912
-
(2005)
J Biol Chem
, vol.280
, pp. 9904-9912
-
-
Neagoe, P.E.1
Lemieux, C.2
Sirois, M.G.3
-
59
-
-
0037087585
-
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors
-
Kuenen B.C., Rosen L., Smit E.F., Parson M.R., Levi M., Ruijter R., et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20 (2002) 1657-1667
-
(2002)
J Clin Oncol
, vol.20
, pp. 1657-1667
-
-
Kuenen, B.C.1
Rosen, L.2
Smit, E.F.3
Parson, M.R.4
Levi, M.5
Ruijter, R.6
-
60
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
Szczylik, C.4
Oudard, S.5
Siebels, M.6
-
61
-
-
33947288597
-
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions
-
Rini B.I. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 13 (2007) 1098-1106
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1098-1106
-
-
Rini, B.I.1
-
62
-
-
33744954585
-
Sunitinib in patients with metastatic renal cell carcinoma
-
Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
-
(2006)
JAMA
, vol.295
, pp. 2516-2524
-
-
Motzer, R.J.1
Rini, B.I.2
Bukowski, R.M.3
Curti, B.D.4
George, D.J.5
Hudes, G.R.6
-
63
-
-
34648827568
-
Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis
-
van Heeckeren W.J., Sanborn S.L., Narayan A., Cooney M.M., McCrae K.R., Schmaier A.H., et al. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol 14 (2007) 468-480
-
(2007)
Curr Opin Hematol
, vol.14
, pp. 468-480
-
-
van Heeckeren, W.J.1
Sanborn, S.L.2
Narayan, A.3
Cooney, M.M.4
McCrae, K.R.5
Schmaier, A.H.6
-
64
-
-
0034074561
-
Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors
-
Perletti G., Concari P., Giardini R., Marras E., Piccinini F., Folkman J., et al. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 60 (2000) 1793-1796
-
(2000)
Cancer Res
, vol.60
, pp. 1793-1796
-
-
Perletti, G.1
Concari, P.2
Giardini, R.3
Marras, E.4
Piccinini, F.5
Folkman, J.6
-
65
-
-
0027970092
-
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
-
O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
-
(1994)
Cell
, vol.79
, pp. 315-328
-
-
O'Reilly, M.S.1
Holmgren, L.2
Shing, Y.3
Chen, C.4
Rosenthal, R.A.5
Moses, M.6
-
66
-
-
33747072903
-
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
-
Kulke M.H., Bergsland E.K., Ryan D.P., Enzinger P.C., Lynch T.J., Zhu A.X., et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24 (2006) 3555-3561
-
(2006)
J Clin Oncol
, vol.24
, pp. 3555-3561
-
-
Kulke, M.H.1
Bergsland, E.K.2
Ryan, D.P.3
Enzinger, P.C.4
Lynch, T.J.5
Zhu, A.X.6
-
67
-
-
29844452745
-
Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University
-
Kurup A., Lin C.W., Murry D.J., Dobrolecki L., Estes D., Yiannoutsos C.T., et al. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 17 (2006) 97-103
-
(2006)
Ann Oncol
, vol.17
, pp. 97-103
-
-
Kurup, A.1
Lin, C.W.2
Murry, D.J.3
Dobrolecki, L.4
Estes, D.5
Yiannoutsos, C.T.6
-
68
-
-
0037151364
-
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
-
Vansteenkiste J., Pirker R., Massuti B., Barata F., Font A., Fiegl M., et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94 (2002) 1211-1220
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1211-1220
-
-
Vansteenkiste, J.1
Pirker, R.2
Massuti, B.3
Barata, F.4
Font, A.5
Fiegl, M.6
|